Effects of silymarin on methotrexate-induced nephrotoxicity in rats

References

• Gorlick R, Goker E, Trippett T, Waltham M, Banerjee B, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukaemia. N Engl J Med. 1996;335:1041–1048
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema AD, Illerhaus G, Ferreri AJ. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma. 2012;53:1867–1875
   PubMed Web of Science ®Google Scholar
• Tannock IF, Boyd NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988;6:1377–1387
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: Incidence, treatment, and outcome. Cancer. 2004;100:2222–2232
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21:252–261
   Web of Science ®Google Scholar
• Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818–822
   PubMed Web of Science ®Google Scholar
• Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382–388
   PubMed Web of Science ®Google Scholar
• Helen STE, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150–3156
   PubMedGoogle Scholar
• Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 1965;25:1018–1024
   PubMed Web of Science ®Google Scholar
• Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30:570–581
   PubMed Web of Science ®Google Scholar
• Smeland E, Fuskevåg OM, Nymann K, et al. High-dose 7-hydroxymethotrexate: Acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol. 1996;37:415–422
   PubMed Web of Science ®Google Scholar
• Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106:459–465
   PubMed Web of Science ®Google Scholar
• Devrim E, Cetin R, Kiliçoğlu B, Ergüder BI, Avci A, Durak I. Methotrexate causes oxidative stress in rat kidney tissues. Ren Fail. 2005;27:771–773
   PubMed Web of Science ®Google Scholar
• Kolli VK, Abraham P, Isaac B, Selvakumar D. Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy. 2009;55:83–90
   PubMed Web of Science ®Google Scholar
• Jahovic N, Cevik H, Sehirli AO. Melatonin prevents methotrexate induced hepatorenal oxidative injury in rats. J Pineal Res. 2003;34:282–287
   PubMed Web of Science ®Google Scholar
• Abdel-Raheem IT, Khedr NF. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:341–353
   PubMed Web of Science ®Google Scholar
• Oktem F, Yilmaz HR, Ozguner F, et al. Methotrexate-induced renal oxidative stress in rats: The role of a novel antioxidant caffeic acid phenethyl ester. Toxicol Ind Health. 2006;22:241–247
   PubMed Web of Science ®Google Scholar
• Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–2063
   PubMed Web of Science ®Google Scholar
• Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124:491–504
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001;15:465–489
   PubMed Web of Science ®Google Scholar
• Metwally MAA, El-Gellal AM, El-Sawaisi SM. Effects of silymarin on lipid metabolism in rats. WASJ. 2009;6:1634–1637
   Google Scholar
• Locher R, Suter PM, Weyhenmeyer R, Vetter W. Inhibitory action of silibinin on low density lipoprotein oxidation. Arzneimittelforschung. 1998;48:236–239
   PubMedGoogle Scholar
• Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007;132:1925–1936
   PubMed Web of Science ®Google Scholar
• Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res. 1998;4:1055–1064
   PubMed Web of Science ®Google Scholar
• Huilgol SV, Jamadar MG. Silymarin, an antioxidant bioflavonoid, inhibits experimentally-induced peptic ulcers in rats by dual mechanisms. Int J Appl Basic Med Res. 2012;2:63–66
   PubMedGoogle Scholar
• Soto C, Mena R, Luna J, et al. Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci. 2004;17:2167–2180
   Google Scholar
• Ninsontia C, Pongjit K, Chaotham C, Chanvorachote P. Silymarin selectively protects human renal cells from cisplatin-induced cell death. Pharm Biol. 2011;49:1082–1090
   PubMed Web of Science ®Google Scholar
• El-Shitany NA, El-Haggar S, El-Desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008;46:2422–2428
   PubMed Web of Science ®Google Scholar
• Varzi H.N., Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi ME. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity. J Vet Pharmacol Therap. 2007;30:477–481
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694–703
   PubMed Web of Science ®Google Scholar
• Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34:427–439
   PubMed Web of Science ®Google Scholar
• Rahiem Ahmed YAA, Hasan Y. Prevention and management of high dose methotrexate toxicity. J Cancer Sci Ther. 2013;5:106–112
   Google Scholar
• Abraham P, Kolli VK, Rabi S. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem Funct. 2010;28:426–433
   PubMed Web of Science ®Google Scholar
• Uzkeser H, Sener E, Bakan E, Hacimuftuoglu A. Preventive role of mirtazapine in methotrexate induced nephrotoxicity in rats. ScienceAsia. 2012;38:129–135
   Google Scholar
• Sener G, Ekşioğlu-Demiralp E, Cetiner M, et al. L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol. 2006;22:47–60
   PubMed Web of Science ®Google Scholar
• Asvadi I, Hajipour B, Asvadi A, Asl NA, Roshangar L, Khodadadi A. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci. 2011;15:1003–1009
   PubMed Web of Science ®Google Scholar
• Zima TAS, Kamenikova L, Janebova M, Buchar E, Crkovska J, Tesar V. The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail. 1998; 20:471–479
   PubMed Web of Science ®Google Scholar
• Prabu SM, Muthumani M. Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rats. Mol Biol Rep. 2012;39:11201–11216
   PubMed Web of Science ®Google Scholar
• Chtourou Y, Garoui el M, Boudawara T, Zeghal N. Protective role of silymarin against manganese-induced nephrotoxicity and oxidative stress in rat. Environ Toxicol. 2014;29:1147–1154
   PubMed Web of Science ®Google Scholar
• Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999;163:6800–6809
   PubMed Web of Science ®Google Scholar